-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Out of Pocket Costs Associated with Biosimilar Use

The panel discusses out of pocket costs and the impact of the 340b program for various patient types.

Episodes in this series

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

A panel of 4 experts on biosimilars

EP. 7 Private Label Biosimilars

EP. 8 Biosimilars in the Commercial Sector

EP. 8 Biosimilars in the Commercial Sector

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 11 Unmet Needs and Future Initiatives

EP. 11 Unmet Needs and Future Initiatives

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 13 Foreseeable Biosimilar Trends

EP. 13 Foreseeable Biosimilar Trends

EP. 14 Legislative Support for Biosimilars

EP. 14 Legislative Support for Biosimilars

EP. 15 Key Takeaways for Biosimilar Utilization

EP. 15 Key Takeaways for Biosimilar Utilization

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH

ByNadege Gunn, MD

June 30th 2026

Experts featured in this series.

Beyond Brand vs. Generic: What Really Drives Treatment Decisions After Repeated Failures

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 30th 2026 | Updated: June 16th 2026

MASH in Focus: How Patient Awareness, Clinical Empowerment, and Research Have Transformed the Field

ByNadege Gunn, MD

June 30th 2026

Experts featured in this series.

When Treatment Isn't Working: Defining Failure and Charting the Next Steps in Psychiatric Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 30th 2026 | Updated: June 16th 2026

Diagnosing and Assessing Atopic Dermatitis: Tools, Scoring Systems, and Patient-Centered Goal Setting

ByAngela J. Lamb, MD

June 29th 2026

Trending on AJMC

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned